TopleyN., MackenzieR., JörresA.Cytokine networks in CAPD: interactions of resident cells during inflammation in the peritoneal cavity.Perit Dial Int1993; 13: S282–5.
2.
TopleyN., WilliamsJ.D.The role of the peritoneal membrane in the control of inflammation in the peritoneal cavity.Kidney Int1994; 46: S71–8.
3.
TopleyN., JörresA., MackenzieR.Interactions of macrophages and mesothelial cells in peritoneal host defence.Nieren-und Hochdruckkrankheiten1994; 23: S88–91.
SlingeneyerA., CanaudB., MionC.Permanent loss of ultrafiltration capacity of the peritoneum in long term peritoneal dialysis: an epidemiological study.Nephron1983; 33: 133–8.
6.
DuweA.K., VasS.I., WeatherheadJ.W.Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis and bactericidal activity in vitro.Infect Immun1981; 33: 130–5.
7.
JörresA., GahlG.M., FreiU.Peritoneal dialysis fluid biocompatibility: does it really matter?Kidney Int1994; 46: S79–86.
8.
HolmesC.J.Biocompatibility of peritoneal dialysis solutions.Perit Dial Int1993; 13: 88–94.
9.
JörresA., TopleyN., WitowskiJ.Impact of peritoneal dialysis solutions on peritoneal immune defence.Perit Dial Int1993; 13: S291–4.
JörresA., TopleyN., WilliamsJ.D.Einfluss der Dialysatzusammensetzung auf die Zytikinproduktion von Leukozyten und peritoneal en Mesothelzellen.Nieren-und Hochdruckkrankheiten1994; 23: S100–4.
13.
WieslanderA.P., NordinM.K., KjellstrandP.T.T.Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929.Kidney Int1991; 40: 77–9.
14.
WieslanderA.P., NordinM.K., MartinsonE.Heat sterilised PD-fluids impair growth and inflammatory responses of cultured cell lines and human leukocytes.Clin Nephrol1993; 39: 343–8.
15.
LiberekT., TopleyN., JörresA.Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH.Nephron1993; 65: 260–5.
16.
WitowskiJ., TopleyN., JörresA.Effect of lactate buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis.Kidney Int1994; 47: 282–93.
17.
LiberekT., TopleyN., JörresA.Peritoneal dialysis fluid inhibition of phagocyte function: effects of osmolality and glucose concentration.J Am Soc Nephrol1993; 3: 1508–15.
18.
KoobsD.H.Phosphate mediation of the Crabtree and Pasteur effects.Science1972; 178: 127–33.
JörresA., GahlG.M., TopleyN.In vitro biocom-patibility of alternative CAPD fluids; comparison of bicarbonate buffered and glucose polymer based solutions.Nephrol Dial Transplant1994; 9: 791–6.
21.
van BronswijkH., VerbrughH.A., BosH.J.Cytotoxic effects of commercial continuous ambulatory peritoneal dialysis (CAPD) fluids and of bacterial exoproducts on human mesothelial cells in vitro.Perit Dial Int1989; 9: 197–202.
22.
AlobaidiH.M., ColesG.A., DaviesM.Host defence in continuous ambulatory peritoneal dialysis: the effect of the dialysate on phagocyte function.Nephrol Dial Transplant1986; 1: 16–21.
23.
JörresA., TopleyN., SteenwegL.Inhibition of cytokine synthesis by peritoneal dialysate persists throughout the CAPD cycle.Am J Nephrol1992; 12: 80–5.
24.
VisserC.E., Brouwer-SteenbergenJ.J.E., BetjesM.G.H.Cancer antigen 125: a bulk marker for mesothelial cell mass in stable peritoneal dialysis patients.Nephrol Dial Transplant1995; 10: 64–9.
25.
YungS., ColesG.A., WilliamsJ.D.The source and possible significance of hyaluronan in the peritoneal cavity.Kidney Int1994; 46: 527–33.
26.
De FijterC.W.H., VerbrughH.A., OeL.P.Peritoneal defence in continuous ambulatory versus continuous cyclic peritoneal dialysis.Kidney Int1992; 42: 947–50.
27.
De FijterC.W.H., VerbrughH.A., OeL.P.Biocompatibility of a glucose polymer-containing peritoneal dialysis fluid.Am J Kidney Dis1993; 4: 411–18.
28.
De FijterC.W.H., VerbrughH.A., PetersE.D.J.In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD.Clin Nephrol1993; 39: 75–80.
29.
De FijterC.W.H., VerbrughH.A., OeP.L.Antibacterial peritoneal defence in automated peritoneal dialysis: advantages of tidal over continuous cyclic peritoneal dialysis?Nephrol Dial Transplant1994; 9: 156–62.
30.
AhmedM.I., RawalP.A., PatelN.M.In vitro buffering capacity of residual peritoneal dialysis fluid: implications for peritoneal dialysis therapy.Artif Organs1992; 16: 416–18.
